Overview of recent definitions of “refractory,” “high-risk,” and “ultra-high risk” CLL
| Source . | Disease state defined . | Definition . |
|---|---|---|
| IWCLL (2008)1 | “Refractory” CLL | Failure to achieve CR/PR, relapse within 6 mo of last treatment |
| EBMT guideline (2007)27 | “High-risk” (consider alloSCT) | Nonresponse or early relapse (within 12 mo) after purine analogs |
| Relapse within 24 mo after having achieved a response with purine analog-based combination therapy or autologous transplantation | ||
| Patients with p53 abnormalities requiring treatment | ||
| Stilgenbauer and Zenz (2010)17 | “Ultra-high risk” | Purine analog (or similar; ie, bendamustine)–refractory CLL |
| Early relapse (within 24 mo) after FCR (or FCR-like) with treatment indication | ||
| TP53 deletion/mutation and indication for treatment |
| Source . | Disease state defined . | Definition . |
|---|---|---|
| IWCLL (2008)1 | “Refractory” CLL | Failure to achieve CR/PR, relapse within 6 mo of last treatment |
| EBMT guideline (2007)27 | “High-risk” (consider alloSCT) | Nonresponse or early relapse (within 12 mo) after purine analogs |
| Relapse within 24 mo after having achieved a response with purine analog-based combination therapy or autologous transplantation | ||
| Patients with p53 abnormalities requiring treatment | ||
| Stilgenbauer and Zenz (2010)17 | “Ultra-high risk” | Purine analog (or similar; ie, bendamustine)–refractory CLL |
| Early relapse (within 24 mo) after FCR (or FCR-like) with treatment indication | ||
| TP53 deletion/mutation and indication for treatment |